<DOC>
	<DOCNO>NCT00531024</DOCNO>
	<brief_summary>Choroidal neovascularisation ( CNV ) age-related macular degeneration one major cause blindness western world . It already know vascular endothelial growth factor ( VEGF ) play major role development CNV . Photodynamic therapy ( PDT ) , subretinal surgery , intravitreal injection VEGF- inhibitor common treatment . These method either invasive need repeat several time long period time order show effect . Furthermore PDT perform eye pigment epithelium detachment ( PED ) maximum 50 % avascular zone , intravitreal injection lead endophthalmitis acute glaucoma . A systemic treatment , would need administer 3 time within 6 week would major effort macular degeneration therapy .</brief_summary>
	<brief_title>Systemic Avastin Therapy Age-Related Macular Degeneration</brief_title>
	<detailed_description>Bevacizumab ( AvastinÂ® , Genentech Inc. ) new anti-vascular endothelial growth factor ( anti-VEGF ) show promising result combination therapy 5-fluorouracil , leucovorin , oxaliplatin first-line treatment metastatic colorectal cancer14,15 . Since intraocular anti-VEGF therapy CNV AMD already show promising result , idea study administer anti-VEGF bevacizumab intravenously , systemic therapy , AMD-patients . The rationale present study determine effect systemic bevacizumab therapy patient fibrovascular pigment epithelium detachment ( PED ) , involve geometric center foveal avascular zone , comparison placebo treatment sodium chloride 0,9 % . The patient receive 3 intravenous infusion 5mg/kg bevacizumab 2 week interval 3 intravenous infusion 100ml sodium chloride 0,9 % 2 week interval . Medical internal review , ETDRS Radner visual acuity assessment , ophthalmologic examination , ocular image OCT 3 , multifocal ERG , fluorescein angiography , indocyanine angiography perform . The follow-up time 6 month .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>AMD patient fibrovascular pigment epithelium detachment ( PED ) , subfoveal choroidal neovascularisations ( CNV ) extend geometric center foveal avascular zone , central retinal thickness least 300 micron . Patients arterial thromboembolic diseases Patients : Cancer , Proteinuria , Renal impairment , Hepatic dysfunction , Vision threaten ophthalmic disease AMD</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Exudative Neovascular</keyword>
	<keyword>AMD</keyword>
	<keyword>Avastin</keyword>
	<keyword>Systemic</keyword>
	<keyword>Exudative Age-Related Macular Degeneration</keyword>
</DOC>